Results from the Largest Known Cholesterol Survey Conducted in the U.S. Announced at the American Heart Association's Annual

   Results from the Largest Known Cholesterol Survey Conducted in the U.S.
   Announced at the American Heart Association's Annual Scientific Sessions

TV Star John O'Hurley, National Lipid Association, Kowa Pharmaceuticals
America, Inc. and Eli Lilly and Company continue education on why patients
stop or switch statin therapy

PR Newswire

LOS ANGELES, Nov. 5, 2012

LOS ANGELES, Nov. 5, 2012 /PRNewswire/ -- Results from the USAGE survey, the
largest known cholesterol survey in the U.S. involving more than 10,100 statin
users^1, were presented today at the American Heart Association's Annual
Scientific Sessions, the leading gathering of cardiovascular disease experts
in the country. John O'Hurley, Seinfeld and Dancing with the Stars actor and
high cholesterol patient, is dedicated to educational efforts in support of
the USAGE survey. As a result of the USAGE survey key findings, tools and
resources were developed to help improve physician-patient dialogue and are
available at

(Logo: )
(Logo: )
(Logo: )

The USAGE survey "Understanding Statin use in America and Gaps in Education,"
is the first survey of its kind to uncover the reasons why patients stop
taking their cholesterol statin medications.^1,2High cholesterol is one of
the leading risk factors of heart disease, the number one cause of death in
the U.S.^3

"When I was first diagnosed with high cholesterol, I struggled with
understanding the seriousness of my health condition," said John O'Hurley.
"Thanks to in-depth conversations with my doctor and a personalized treatment
plan including diet and exercise, I have lowered my cholesterol levels and am
taking control of my health. It is my hope that the USAGE survey tools and
resources help patients to understand the importance of managing high
cholesterol and give them clearer direction on how to address concerns with
their doctor."

While doctors write more than 200 million prescriptions for statins each year,
adherence to treatment remains a significant issue.^4 Previous studies
indicate that nearly 75% of new statin users stop therapy by the end of the
first year.^5 Problems with statin adherence are associated with an increased
risk of adverse cardiovascular outcomes—including heart attack and death^6—
and contribute to the rising costs of heart disease; expected to reach $818
billion by 2030.^3

"Many patients ignore their doctor's concerns about high cholesterol levels,
or fail to take their statin as prescribed," said Dr. Eliot Brinton, spokesman
for the National Lipid Association, who also serves as Director of
Atherometabolic Research at the Utah Foundation for Biomedical Research. "It
is important for doctors and patients to work together as a team to make sure
the appropriate treatments—diet, lifestyle and a statin, if needed—are
prescribed and followed properly. The USAGE survey results can help educate
healthcare providers and the general public about the importance of
cholesterol management and will empower patients to take action against this
critical health issue."

The USAGE survey explored patient perceptions, attitudes and behaviors about
statins, from reasons why patients stopped treatment to education around
therapeutic lifestyle changes and the high incidence of potential drug-drug
interactions (DDIs).

  oThe USAGE survey shows side effects and cost are the paramount concerns
    for patients who stop taking their statins:^2

       oSide effects (62%) and cost (17%) emerged as the leading reasons why
         survey respondents stopped taking their statin, with lack of
         treatment efficacy (12%) cited as third most important.
       oWhile 85% of respondents cited their doctors as one of their two most
         valuable sources for health information, 34% discontinued their
         statin without consulting their doctor.

  oWhile 81% of patients surveyed report being satisfied with their doctor's
    explanation of treatment, there is still room for improvement in the
    doctor-patient dialogue:^2

       oRecollection of cholesterol levels is poor—respondents were more
         likely to remember their pant size from high school than their most
         recent cholesterol level (64% vs. 46%).
       oThe average respondent uses three prescription and/or
         non-prescription products with drug-drug interaction potential; yet
         only 38% of all respondents stated they were concerned with potential
         drug interactions.
       oImportantly, four out of ten respondents (42%) who are concerned
         about DDIs but did not speak with their doctor about it say they rely
         on their pharmacist to identify potential interactions. While
         discussions at the pharmacy are important, it is also critical for
         doctors to be a part of this conversation to address concerns about
         potential DDIs.

Helping to fill the gaps in education about statin use, the USAGE survey
website provides downloadable tools and resources, including patient- and
medical provider-directed Discussion Guides, a Medication Tracker and
presentation for healthcare providers to educate others in the medical
community about the USAGE survey and its findings. For more information about
the USAGE survey, please visit

About the USAGE Survey
The USAGE survey was fielded from September 21, 2011 to October 17, 2011 via
an Internet-based, self-administered questionnaire developed by Kantar
Health. All participants self-reported they were over 18 years old and
diagnosed with high cholesterol by a doctor. Survey respondents were
predominantly Caucasian (92%), female (61%), middle income ($62,912/yr), with
health insurance (93%) and with a mean age of 61 years.

About the National Lipid Association
The National Lipid Association (NLA) is a nonprofit, multidisciplinary medical
society focused on enhancing the practice of lipid management in clinical
medicine. The NLA represents more than 3,000 members in the United States and
provides continuing medical education for physicians and other healthcare
professionals to advance professional development and promote certification in
clinical lipidology.

About Kowa Pharmaceuticals America, Inc.
Kowa Pharmaceuticals America, Inc. (KPA) is a pharmaceutical company
specializing primarily in the area of cardiometabolic diseases. The company,
started in 2001 as ProEthic Pharmaceuticals, Inc., was acquired by Kowa
Company, Ltd. in September of 2008. A privately held company, KPA directs its
efforts towards the acquisition, licensing and marketing of pharmaceutical

About Eli Lilly and Company (NYSE: LLY)
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers—through medicines and information—for some of the world's most urgent
medical needs. Additional information about Lilly is available at


GEN-0007 MG80426

^1 Data on File: Cholesterol Statin Surveys Audit

^2 Data on File: Statin USAGE Survey; Slides 1-76

^3 Heidenreich, Paul A., "Forecasting the Future of Cardiovascular
Disease in the United States: A Policy Statement From the American Heart
Association." Circulation 123 (2011): 933-944. Print.

^4 Data on File: Wolters Kluwer Pharma Solutions, Source ® Pharmaceutical
Audit Suite, Retail Prescription Monthly, January – December 2011

^5 Tsuyuki, et al., "Poor Adherence with Hypolipidemic Drugs: A Lost
Opportunity", Pharmacotherapy 2001;21(5):579.

^6 McGinnis BD, Olson KL, Delate TM, Stolcpart RS: Statin adherence and
mortality in patients enrolled in a secondary prevention program. Am J Manag
Care. 2009;15:689-95. 

SOURCE National Lipid Association; Kowa Pharmaceuticals America, Inc.; Eli
Lilly and Company

Contact: Eliza Merves, Makovsky + Company Inc. for Kowa Pharmaceuticals
America, Inc., +1(212) 508-9631, Mobile: +1(908) 256-1243,; or Lisa Garman, Kowa Pharmaceuticals America, Inc.,
Office: +1-(334) 288-1288, Mobile: +1-(404) 291-4772,;
or Tina Gaines, Eli Lilly and Company, Office: +1-(317) 276-3845, Mobile:
+1(317) 366-2568,; or Judi Spann, National
Lipid Association, Office: +1(904) 309-6222, Mobile: +1(850) 322-9817,
Press spacebar to pause and continue. Press esc to stop.